Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSC), has entered an agreement to grant Novo Nordisk a non-exclusive right to use its iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.
Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem cells (iPSCs), has appointed Ilyas Singeç, MD, as chief scientific officer effective September 12. In this newly created strategic role, Dr. Singeç will define the company’s future iPSC technological pipeline. In his role as part of the company’s executive leadership team, he will also help drive business strategy with the goal of transforming scientific research and healthcare by using iPSC technologies.
Promega and Fujifilm Cellular Dynamics Enter Assay Development Partnership
Clinical stage biotechnology company Cynata Therapeutics has secured a manufacturing services agreement with specialised human cell manufacturing heavyweight, Fujifilm Cellular Dynamics, to produce Cynata’s Cymerus therapeutic stem cell products. The new agreement allows Cynata to leverage Fujifilm’s extensive experience in the cell therapy manufacturing space.
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, a joint venture of Fujifilm Cellular Dynamics (FCDI) and David Gamm, focusing on developing cell therapies for patients with ocular diseases, have entered into a strategic research and development (R&D) alliance.